Rare Disease Equity
Advancing Equity in Rare Disease Trials: Global Realities, Local Solutions
Rose Blackburne, M.D., MBA; Radojica Savic, M.D.; Galina Nesterova, MD
PPD clinical research business of Thermo Fisher Scientific
PAO-05-25-CL-02Jul 23, 2025
Clinical Diversity
Staying the Course: Sustaining Equity in Clinical Trials Amid Headwinds
Tegan Mead
Javara
PAO-06-25-CL-05BJun 12, 2025
Clinical Diversity
Redefining Access: Embedding Diversity into the Clinical Research Ecosystem
Tegan Mead
Javara
PAO-06-25-CL-05AJun 12, 2025
NIH
The White House’s War on the NIH and the Disasters Ahead
David Alvaro, Ph.D.
Pharma's Almanac
PAO-03-25-NI-05Mar 24, 2025
Diversity
Fighting for Diversity and Equity in Pharma and Biopharma
David Alvaro, Ph.D.
Pharma's Almanac
PAO-25-30-05Mar 06, 2025
Clinical Trials Representation
Leveraging Decentralized Clinical Trial Strategies to Reduce Health Care Disparities
Jennifer Urwongse
PPD clinical research business of Thermo Fisher Scientific
PAO-03-24-CL-05Mar 13, 2024
Column: Clinical Trials
CAR-T Study Shines New Spotlight on Clinical Trials Representation
David Alvaro, Ph.D.
Pharma's Almanac
PAO-06-022--NI-06Jul 02, 2022
Business Leadership
Former Surgeon General Jerome Adams Announced as Chairman of the Board of Total Diversity Clinical Trial Management
TOTAL Diversity Clinical Trial Management
PR-M03-22-04Mar 08, 2022
Genentech Launches Oncology Clinical Trial Diversity Alliance
Genentech
PR-M06-21-031Jun 24, 2021
Corporate Social Responsibility
Life Imitating Science: Arranta Bio’s Commitment to Corporate Social Responsibility and Diversity
Susan Surabian; Melanie Cerullo
Arranta Bio
PAP-Q4-20-CL-002Dec 09, 2020
Culture
Is the Pharma Industry Developing Cultural Intelligence?
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAP-Q1-20-NI-010Mar 19, 2020
Corporate Social Responsibility
Giving Structure to a Long-Term CSR Strategy
Vincent Minvielle
Servier
PAP-Q4-19-CL-030Dec 06, 2019